LWAM
CKPT

Legacy Wealth Asset Management’s Checkpoint Therapeutics CKPT Stock Holding History

Legacy Wealth Asset Management’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-85,000
Closed -$272K – 346
2024
Q4 		$272K Hold
85,000
– – 0.07% 318
2024
Q3 		$190K Hold
85,000
– – 0.05% 340
2024
Q2 		$183K Hold
85,000
– – 0.05% 331
2024
Q1 		$174K Hold
85,000
– – 0.05% 337
2023
Q4 		$195K Hold
85,000
– – 0.06% 329
2023
Q3 		$145K Buy
85,000
+43,500
+105% +$98.9K 0.05% 325
2023
Q2 		$103K Buy
+41,500
New +$113K 0.04% 331

Other funds holding CKPT

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.46% 1-Year Est. Return
GLF
Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

Legacy Wealth Asset Management's CKPT Position: Q1 2025 in Review

Legacy Wealth Asset Management sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 85,000 shares — an estimated $272K sold.

Legacy Wealth Asset Management first reported a position in CKPT in Q2 2023 and held it in 7 quarters. The position peaked at $272K in Q4 2024. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

  • Legacy Wealth Asset Management reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Legacy Wealth Asset Management sold 85,000 Checkpoint Therapeutics shares in Q1 2025, an estimated $272K.
  • Legacy Wealth Asset Management first reported a position in Checkpoint Therapeutics in Q2 2023 and held it in 7 quarters.
  • Legacy Wealth Asset Management's Checkpoint Therapeutics position peaked at $272K in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on Legacy Wealth Asset Management's 13F filing for Q1 2025, filed 9 Apr 2025.